Study of Duloxetine in Elderly Patients With Major Depressive Disorder

Lilly

Status and phase: Completed; Phase 3

Conditions: Depression; Cognition

Treatments: Drug: Placebo; Drug: Duloxetine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00062673

F1J-MC-HMBV

6091

Details and patient eligibility

About

A study of the safety and efficacy of duloxetine in elderly patients (greater than 65 years old) with major depressive disorder

Full description

Duloxetine 60 mg QD and placebo variable-duration, placebo lead-in period 9 weeks in the acute treatment phase

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• You must be able to visit the doctor's office for clinic visits, tests, and procedures.
• You must have been diagnosed with major depression, and have had at least one other episode in the past.

Exclusion criteria

• You have a current or previous major psychiatric disorder other than depression, such as bipolar disorder, schizophrenia, or other psychotic disorder.
• You have taken a drug within the last 30 days that has not been approved for use by governmental authorities.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind